Compare CCO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | NVCR |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2005 | 2015 |
| Metric | CCO | NVCR |
|---|---|---|
| Price | $2.39 | $17.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $2.12 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 4.3M | 1.7M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.81 | 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | $655,353,000.00 |
| Revenue This Year | $5.35 | $7.72 |
| Revenue Next Year | $4.26 | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.57 | ★ 8.28 |
| 52 Week Low | $1.00 | $9.82 |
| 52 Week High | $2.43 | $20.05 |
| Indicator | CCO | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 67.38 |
| Support Level | $2.37 | $12.66 |
| Resistance Level | $2.41 | N/A |
| Average True Range (ATR) | 0.01 | 1.01 |
| MACD | -0.00 | 0.23 |
| Stochastic Oscillator | 25.00 | 82.42 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.